| 17.12 -0.1 (-0.58%) | 03-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 20.86 | 1-year : | 22.09 |
| Resists | First : | 17.86 | Second : | 18.91 |
| Pivot price | 17.9 |
|||
| Supports | First : | 16.17 | Second : | 13.45 |
| MAs | MA(5) : | 17.4 |
MA(20) : | 17.7  |
| MA(100) : | 16.63 |
MA(250) : | 14.77 |
|
| MACD | MACD : | 0 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 33.1 |
D(3) : | 40.6 |
| RSI | RSI(14): 43.2 |
|||
| 52-week | High : | 18.91 | Low : | 10.44 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BLCO ] has closed above bottom band by 10.0%. Bollinger Bands are 23.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.51 - 17.6 | 17.6 - 17.68 |
| Low: | 16.64 - 16.75 | 16.75 - 16.85 |
| Close: | 16.92 - 17.09 | 17.09 - 17.26 |
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Tue, 10 Mar 2026
Bausch + Lomb (NYSE:BLCO) CEO Purchases $251,958.00 in Stock - MarketBeat
Tue, 10 Mar 2026
A Robert Bailey Buys 14,600 Shares of Bausch + Lomb (NYSE:BLCO) Stock - MarketBeat
Tue, 10 Mar 2026
Bausch And Lomb (NYSE:BLCO) Glaucoma Moves Catch Market Eyes Nyse Composite Today - Kalkine Media
Tue, 10 Mar 2026
(BLCO) Investment Analysis and Advice (BLCO:CA) - Stock Traders Daily
Tue, 10 Mar 2026
A Look At Bausch + Lomb (NYSE:BLCO) Valuation As Glaucoma Pipeline Webinar Draws Fresh Attention - simplywall.st
Mon, 09 Mar 2026
Bausch + Lomb Launches R&D Webinar Series Spotlighting Glaucoma Pipeline - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 354 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 89 (%) |
| Held by Institutions | 10.5 (%) |
| Shares Short | 3,160 (K) |
| Shares Short P.Month | 3,680 (K) |
| EPS | -1.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.2 |
| Profit Margin | -7.1 % |
| Operating Margin | 11.2 % |
| Return on Assets (ttm) | 0.8 % |
| Return on Equity (ttm) | -5.4 % |
| Qtrly Rev. Growth | 9.8 % |
| Gross Profit (p.s.) | 8.6 |
| Sales Per Share | 14.39 |
| EBITDA (p.s.) | 1.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 283 (M) |
| Levered Free Cash Flow | 141 (M) |
| PE Ratio | -16.79 |
| PEG Ratio | 0 |
| Price to Book value | 0.94 |
| Price to Sales | 1.18 |
| Price to Cash Flow | 21.43 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|